查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995465

肺炎鏈球菌檢測市場：2026-2032年全球市場預測（依檢測類型、技術、應用、最終用戶和通路分類）

Pneumococcal Testing Market by Type Of Test, Technology, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺炎球菌檢測市場價值將達到 28.5 億美元，到 2026 年將成長至 30.5 億美元，到 2032 年將達到 49.4 億美元，複合年成長率為 8.16%。

主要市場統計數據
基準年 2025 28.5億美元
預計年份：2026年 30.5億美元
預測年份 2032 49.4億美元
複合年成長率 (%) 8.16%

一份策略指南，揭示了診斷技術的最新進展、臨床需求和監測需求如何改變肺炎球菌檢測和檢查室的優先事項。

肺炎鏈球菌感染仍然是臨床和公共衛生領域面臨的複雜挑戰，診斷技術的進步對於改善患者預後和製定預防策略至關重要。目前，診斷技術的發展取決於三個要素：分子層面的準確性、快速的照護現場以及以監測主導的公共衛生干預。因此，實驗室主任、臨床微生物學家和公共衛生官員必須結合實際操作限制和監管要求，以權衡診斷的準確性、能力和速度。

技術進步、整合資料系統和不斷發展的臨床路徑如何從根本上改變肺炎球菌檢測和監測方法。

肺炎鏈球菌檢測領域正經歷一場變革，其驅動力包括技術成熟、臨床路徑轉變以及公共衛生重點的演變。能夠一次檢測多個標靶的高靈敏度分子診斷方法，正加速人們擺脫對傳統培養方法的依賴。同時，血清學技術也得到了改進，能夠更快地檢測抗體和抗原，從而更迅速地評估免疫狀態和疫苗效力。

評估 2025 年關稅措施將如何影響整個肺炎鏈球菌診斷生態系統的籌資策略、供應鏈韌性和平台選擇。

2025年關稅的實施對肺炎球菌檢測所需材料和設備的採購、生產和分銷產生了多方面的影響。進口關稅和貿易調整影響了試劑、設備和耗材的採購決策，促使許多相關人員重新評估其供應商組合和供應鏈韌性。因此，診斷試劑生產商和檢測實驗室正在審查其生產和庫存策略，以維持檢測服務的連續性。

詳細的細分分析揭示了測試方法、底層技術、臨床應用、最終用戶環境和分銷模式如何全面推動診斷方法的採用。

了解市場區隔對於制定產品開發、市場准入和檢查室部署策略至關重要。從檢測類型來看，市場涵蓋培養檢測、分子檢測和血清學檢測。基於培養的檢測方法仍然是抗菌藥物敏感性試驗和最終鑑定的關鍵，其分為可提高處理能力的自動化培養系統和在許多診斷流程中必不可少的傳統培養方法。分子檢測的特點是數位PCR、多重PCR和即時PCR等技術的興起，這些技術能夠快速、高靈敏度地檢測和同時分析多個標靶。血清學方法，包括酵素免疫分析法（ELISA）和快速免疫檢測測定，可用於評估免疫狀態和監測疫苗反應。 ELISA平台通常用於詳細的血清分型和抗體譜分析，而快速免疫檢測則適用於分散式環境。

一項區域比較分析，檢驗政策框架、檢查室能力和供應鏈策略如何影響世界各地市場的肺炎球菌檢測。

區域趨勢顯著影響診斷方法的採用、監管路徑和投資重點。在美洲，臨床檢查室和公共衛生機構優先考慮快速、高通量檢測，以支援臨床管理和更廣泛的監測需求。儘管該地區的醫療保健系統傾向於採用與電子健康記錄和公共衛生報告基礎設施整合的多重檢測和分子診斷平台，但保險公司系統則在檢測路徑的選擇上更加重視成本效益和價值。

提供可操作的企業級洞察，展示平台策略、策略夥伴關係和營運支援如何決定肺炎球菌診斷領域的成功。

在企業層面，發展趨勢聚焦於平台多元化、策略夥伴關係以及調整經營模式以適應檢查室不斷變化的需求。診斷試劑製造商正增加對涵蓋中心檢查室設備、患者端分析儀和耗材生態系統的產品組合的投資，以確保持續的收入並深化客戶關係。這一趨勢促使人們更加關注能夠進行多參數檢測、血清分型以及與數位化報告工具整合的測試，從而支援監測和臨床決策。

針對診斷和檢查室領導者的具體策略行動，以增強互通性、供應鏈韌性、證據產生和客製化商業化方法。

產業領導者應優先採取一系列切實可行的措施，以鞏固市場地位並支持公共衛生目標。首先，隨著檢查室對設備、實驗室資訊系統和公共衛生資料庫之間無縫連接的需求日益成長，投資於平台互通性和數據整合能力將有助於技術的普及應用。透過消除整合障礙，企業可以縮短客戶獲得價值的時間，並加強與客戶的長期合作關係。

結合相關人員訪談、文獻整合和跨領域分析的綜合性混合調查方法，得出了切實可行的診斷和政策見解。

這些研究結果是基於多模態方法，以確保研究的整體性和可操作性。主要研究包括對實驗室主任、臨床微生物學家、採購經理和公共衛生官員進行結構化訪談和定性聽證，以了解第一線操作人員的觀點和決策標準。這些相關人員提供了關於平台選擇、檢驗要求和供應鏈脆弱性的詳細背景信息，這有助於解讀診斷和監測領域的新興趨勢。

最終整合突顯了技術創新、供應鏈穩健性和協調的公共衛生策略之間的相互作用，以減輕肺炎球菌疾病的負擔。

總之，肺炎球菌檢測領域正處於技術能力、供應鏈現狀和公共衛生優先事項交匯的十字路口。分子和定序技術正在開闢新的診斷和監測途徑，而血清學檢測和即時檢測（POC​​T）則在分散式環境中持續擴大檢測範圍。這些互補的方法為臨床醫生和公共衛生部門提供了更全面的工具，但也需要更加重視互通性、檢驗和品質保證。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按檢測類型分類的肺炎鏈球菌檢測市場

  • 培養方法
    • 自動培養
    • 傳統文化
  • 分子
    • 數位PCR
    • 多重PCR
    • 即時PCR
  • 血清學
    • ELISA
    • 快速免疫檢測

第9章：肺炎鏈球菌檢測市場：依技術分類

  • ELISA
    • 間接ELISA
    • 夾心ELISA
  • 層析法
    • 點印法
    • 橫向流動化驗
  • 次世代定序
    • Illumina平台
    • Ion Torrent
  • PCR檢測
    • 數位PCR
    • 多重PCR
    • 即時PCR

第10章：肺炎鏈球菌檢測市場：依應用領域分類

  • 攜帶者篩檢
    • 鼻咽篩檢
    • 口腔和咽部篩檢
  • 診斷
    • 社區型肺炎
    • 腦膜炎
    • 中耳炎
  • 監視
    • 抗菌素抗藥性監測
    • 血清型分佈
  • 疫苗評估
    • 上市後監測
    • 臨床前試驗

第11章 肺炎鏈球菌檢測市場：依最終用戶分類

  • 診所
    • 社區健康中心
    • 門診部
  • 醫院
    • 大型醫院
    • 小規模醫院
  • 公共衛生檢測實驗室
    • 當地公共衛生實驗室
    • 州公共衛生研究所
  • 參考檢測實驗室
    • 國家參考實驗室
    • 區域參考檢測實驗室

第12章：肺炎鏈球菌檢測市場：依通路分類

  • 直銷
    • 線上直銷
    • 專業銷售團隊
  • 銷售代理
    • 區域銷售代理
    • 全國銷售代理
  • 線上
    • EC平台
    • 製造商門戶

第13章：肺炎鏈球菌檢測市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 肺炎鏈球菌檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 肺炎鏈球菌檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國肺炎鏈球菌檢測市場

第17章：中國肺炎鏈球菌檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Meridian Bioscience Inc.
  • QIAGEN NV
  • Seegene Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-4103B31E098A

The Pneumococcal Testing Market was valued at USD 2.85 billion in 2025 and is projected to grow to USD 3.05 billion in 2026, with a CAGR of 8.16%, reaching USD 4.94 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.85 billion
Estimated Year [2026] USD 3.05 billion
Forecast Year [2032] USD 4.94 billion
CAGR (%) 8.16%

A strategic primer highlighting how recent diagnostic advances, clinical imperatives, and surveillance needs are reshaping pneumococcal testing and laboratory priorities

Pneumococcal disease continues to present a complex clinical and public health challenge, and advances in testing are central to improving patient outcomes and informing prevention strategies. Diagnostics now operate at the intersection of molecular precision, rapid point-of-care delivery, and surveillance-driven public health interventions. As a result, laboratory directors, clinical microbiologists, and public health officials must weigh diagnostic accuracy, throughput, and timeliness against operational constraints and regulatory expectations.

Over recent years, diagnostic innovation has shifted the emphasis from purely culture-based identification to more nuanced molecular and serological approaches that enable earlier and more specific detection. This evolution aligns with expanding vaccination programs and heightened surveillance needs for serotype distribution and antibiotic resistance. Simultaneously, healthcare systems are recalibrating procurement and laboratory pathways to accommodate multiplexed platforms and integrated data reporting capabilities that better support clinical decision-making and epidemiological tracking.

In this context, stakeholders must balance near-term clinical utility with longer-term investments in infrastructure, workforce training, and information systems. The introduction of novel assays and analytic technologies demands careful validation and adoption strategies that preserve diagnostic quality while optimizing for real-world constraints. Ultimately, the choices made today in test selection, laboratory workflow, and surveillance design will define the next generation of pneumococcal control measures and their capacity to reduce morbidity and mortality.

How converging technological advances, integrated data systems, and shifting clinical pathways are fundamentally transforming pneumococcal testing and surveillance approaches

The landscape of pneumococcal testing is undergoing transformative shifts driven by technological maturation, changing clinical pathways, and evolving public health priorities. Molecular approaches that offer heightened sensitivity and the ability to detect multiple targets in a single assay are fostering a move away from sole reliance on traditional culture methods. At the same time, serological techniques have been refined for faster antibody and antigen detection, enabling more rapid assessments of immune status and vaccine effectiveness.

Testing is also becoming more integrated with digital health and laboratory information systems, which enhances data flow between clinical settings and public health authorities. This integration supports real-time surveillance of serotype prevalence and resistance patterns, and it enables more rapid public health responses. Furthermore, the diversification of point-of-care testing options is widening access in outpatient and community settings, thereby altering specimen collection pathways and diagnostic stewardship models.

Another significant shift is the emphasis on multiplexing and genomic methods that allow simultaneous pathogen identification and characterization. These approaches facilitate precise epidemiological tracking and inform vaccine policy decisions, while also placing new demands on laboratory bioinformatics and data governance. As a consequence, collaborations across diagnostic manufacturers, clinical laboratories, and public health institutions are accelerating, and strategic partnerships are increasingly central to deploying scalable, sustainable testing solutions.

Assessment of how 2025 tariff measures have reshaped procurement strategies, supply chain resiliency, and platform selection across the pneumococcal diagnostics ecosystem

The introduction of tariffs in 2025 has had a multi-dimensional impact on the procurement, manufacturing, and distribution dynamics for pneumococcal testing supplies and equipment. Import duties and trade adjustments have influenced sourcing decisions for reagents, instruments, and consumables, prompting many stakeholders to reassess supplier portfolios and supply chain resiliency. In turn, diagnostic manufacturers and laboratory networks are recalibrating production and inventory strategies to maintain continuity of testing services.

Operationally, laboratories faced decisions about prioritizing existing platforms versus investing in alternative technologies that are less exposed to tariff-driven price volatility. Procurement teams responded by negotiating long-term supply agreements, expanding local distributor relationships, and in some cases accelerating investments in domestic production capacities. These shifts have also affected lead times and logistics planning, with organizations placing greater emphasis on dual-source strategies and buffer stock to mitigate disruptions.

Policy responses have been notable, with regulators and payers engaging to ensure access to essential diagnostics while balancing cost containment goals. Payers and hospital administrators intensified scrutiny of test utilization to preserve budgetary stability, which in turn influenced adoption timelines for higher-cost platforms. At the same time, tariff pressures catalyzed regionalization of supply chains, encouraging partnership models that prioritize supply security and compliance with local market requirements. Taken together, these dynamics underscore the importance of strategic procurement, flexible platform selection, and proactive supply chain governance in preserving diagnostic capacity under changing trade conditions.

In-depth segmentation analysis revealing how test modalities, enabling technologies, clinical applications, end-user settings, and distribution models collectively drive diagnostic adoption

Understanding segmentation is essential for aligning product development, market access, and laboratory adoption strategies. From a test-type perspective, the market spans culture based methods, molecular assays, and serological tools. Culture based testing remains relevant for antimicrobial susceptibility and confirmatory identification, and it is split across automated culture systems that improve throughput and conventional culture methods that remain indispensable in many diagnostic workflows. Molecular testing is characterized by the rise of digital PCR, multiplex PCR, and real time PCR modalities that deliver rapid, sensitive detection and enable simultaneous analysis of multiple targets. Serological approaches-encompassing enzyme-linked immunosorbent assays and rapid immunoassays-support immune status evaluation and vaccine response monitoring, with ELISA platforms commonly used for detailed serotype and antibody profiling while rapid immunoassays serve decentralized settings.

Technology segmentation further clarifies the competitive and clinical landscape. ELISA platforms are differentiated into indirect and sandwich formats that address diverse antigen-antibody dynamics, while immunochromatographic tests include dot blot and lateral flow assay formats suitable for rapid screening and point-of-care use. Next-generation sequencing platforms such as Illumina and Ion Torrent offer high-resolution serotype distribution and genomic surveillance capabilities, enabling deep insights into pathogen evolution. PCR assays remain a cornerstone technology with digital PCR offering absolute quantification, multiplex PCR enabling broadened target panels, and real time PCR providing a balance of speed and analytical performance.

Application-driven segmentation highlights how diagnostic utility varies across carrier screening, diagnosis, surveillance, and vaccine evaluation. Carrier screening practices differentiate nasopharyngeal and oropharyngeal sampling approaches, whereas diagnostic use spans clinical syndromes such as community-acquired pneumonia, meningitis, and otitis media. Surveillance activities focus on antibiotic resistance monitoring and serotype distribution to inform public health interventions, and vaccine evaluation relies on both preclinical trial data and postmarketing surveillance to measure real-world vaccine impact. End-user segmentation addresses the operational contexts in which tests are deployed, ranging from community health centers and outpatient clinics to large and small hospitals, local and state public health laboratories, and national and regional reference laboratories, each with distinct workflow, regulatory, and budget considerations. Finally, distribution channels vary across direct sales-whether via online direct portals or specialty sales teams-distributors operating at local and national scales, and online platforms that include ecommerce offerings and manufacturer portals, creating multiple go-to-market pathways and service models that suppliers must optimize to reach diverse buyers.

Comparative regional insights examining how policy frameworks, laboratory capacity, and supply chain strategies shape pneumococcal testing across global markets

Regional dynamics exert a major influence on diagnostic deployment, regulatory pathways, and investment priorities. In the Americas, clinical laboratories and public health agencies place emphasis on rapid, high-throughput testing to support both clinical management and broad surveillance needs. Health systems in this region tend to adopt multiplex and molecular platforms that integrate with electronic health records and public health reporting infrastructures, while payer systems drive consideration of cost-effectiveness and value-based testing pathways.

Europe, Middle East & Africa presents a heterogeneous landscape where regulatory frameworks, reimbursement models, and public health priorities vary significantly. In some territories, sophisticated reference laboratories and national surveillance programs leverage next-generation sequencing and genomic epidemiology to map serotype shifts, whereas in lower-resource settings there is greater reliance on point-of-care serological and immunochromatographic tests to expand access. Cross-border collaboration and capacity building remain central themes, and stakeholders increasingly prioritize harmonized data standards to enable comparable surveillance outputs across jurisdictions.

In the Asia-Pacific region, growth in diagnostic infrastructure and investments in local manufacturing are notable, with governments and private stakeholders emphasizing domestic capability for reagent production and instrument servicing. This region demonstrates rapid adoption of digital workflows and decentralized testing models, and it is an active arena for public-private collaborations aimed at scaling surveillance and vaccine evaluation programs. Across all regions, supply chain strategies and regulatory engagement are tailored to local market structures, and vendors must design flexible commercial models that account for these regional differences while ensuring quality and compliance.

Practical company-level intelligence showing how platform strategies, strategic partnerships, and operational support determine success in the pneumococcal diagnostics arena

Company-level dynamics center on platform diversification, strategic partnerships, and the alignment of commercial models with evolving laboratory needs. Diagnostic manufacturers are increasingly investing in product families that span central laboratory instruments, near-patient analyzers, and consumable ecosystems to secure recurring revenue and deepen customer relationships. This trend is accompanied by heightened focus on assays that enable multiplex detection, serotype differentiation, and integration with digital reporting tools that support surveillance and clinical decision support.

Partnerships between assay developers, instrument suppliers, and informatics providers are becoming more common as firms seek to offer end-to-end solutions that reduce implementation friction for laboratories. Similarly, contract manufacturing organizations and specialty reagent suppliers play an important role in ensuring supply continuity, particularly when geopolitical or trade policy changes introduce procurement uncertainty. Market competitors are also investing in regulatory pathways and clinical evidence generation to support broader indications, including use cases in outpatient settings and public health surveillance.

Laboratory networks and reference institutions exert influence through validation studies, protocol harmonization, and participation in external quality assessment programs, which in turn shape adoption patterns for new assays. Companies that demonstrate strong postmarket support, rapid technical service, and accessible training resources tend to achieve deeper penetration in decentralized settings. Overall, the most successful firms combine technological differentiation with pragmatic commercialization strategies that address the operational realities of diverse end users.

Concrete strategic actions for diagnostic and laboratory leaders to enhance interoperability, supply chain resilience, evidence generation, and tailored commercialization approaches

Industry leaders should prioritize a set of actionable measures to solidify market position and support public health objectives. First, investing in platform interoperability and data integration capabilities will improve adoption, as laboratories increasingly require seamless connectivity between instruments, laboratory information systems, and public health databases. By addressing integration barriers, companies can accelerate time-to-value for customers and strengthen long-term relationships.

Second, enhancing supply chain resilience through diversified sourcing, regional manufacturing partnerships, and scalable inventory strategies will reduce exposure to trade-related disruptions and tariff volatility. Strategic procurement arrangements and transparent communication with customers about lead times and contingency plans will bolster trust and operational continuity. Third, targeted evidence generation that validates performance across clinical syndromes, specimen types, and demographic populations will support broader clinical acceptance and regulatory flexibility. Robust postmarket surveillance and real-world performance data will also inform iterative product improvements.

Fourth, tailoring go-to-market approaches to end-user needs-differentiating offerings for community clinics, large hospital systems, public health labs, and reference laboratories-will improve market penetration. This includes offering modular training, remote support, and flexible commercial terms that reflect the purchasing realities of each segment. Finally, companies should engage proactively with public health stakeholders and payers to align diagnostic value propositions with policy priorities and reimbursement frameworks. These combined actions will help leaders navigate uncertainty while delivering durable clinical and public health value.

Comprehensive blended research methodology combining stakeholder interviews, literature synthesis, and cross-segmentation analysis to produce pragmatic diagnostic and policy insights

The research underpinning these insights combined a multi-modal approach to ensure comprehensiveness and practical relevance. Primary research included structured interviews and qualitative consultations with laboratory directors, clinical microbiologists, procurement leads, and public health officials to capture on-the-ground operational perspectives and decision criteria. These stakeholder engagements provided detailed context on platform selection, validation requirements, and supply chain sensitivities, and they informed the interpretation of emerging trends in diagnostics and surveillance.

Secondary research synthesized publicly available regulatory guidance, technical white papers, and peer-reviewed literature on pneumococcal diagnostics, serotype epidemiology, and testing methodologies. Emphasis was placed on peer-reviewed validation studies and official public health communications to ensure that technological assessments were grounded in rigorous evidence. Where appropriate, company disclosures and product technical specifications were reviewed to map feature sets and integration capabilities across competing platforms.

Analytical methods included cross-segmentation mapping to identify where clinical needs intersect with technological capabilities, and scenario analysis to explore how supply chain or policy shifts could alter adoption pathways. Quality assurance measures involved validation of qualitative findings with multiple independent sources and iterative review by clinical experts to ensure that interpretations reflected practical realities. This blended methodology supports robust, actionable insights that can guide procurement decisions, platform investments, and policy engagement.

Final synthesis emphasizing the interplay between technological innovation, supply chain robustness, and collaborative public health strategies to reduce pneumococcal disease burden

In closing, the pneumococcal testing environment is at an inflection point where technological capability, supply chain realities, and public health priorities converge. Molecular and sequencing technologies are unlocking new diagnostic and surveillance possibilities, while serological assays and point-of-care formats continue to expand access in decentralized settings. These complementary modalities create a richer toolkit for clinicians and public health authorities but also demand greater attention to interoperability, validation, and quality assurance.

The cumulative effect of recent policy changes and trade dynamics has reinforced the need for resilient procurement strategies and adaptable commercial models. At the same time, regional differences in regulatory and laboratory capacity require suppliers to offer flexible deployment options that account for local constraints and priorities. Companies and laboratory networks that proactively address integration, evidence generation, and supply security will be best positioned to support both immediate clinical needs and longer-term public health objectives.

Ultimately, successful navigation of this landscape depends on close collaboration across manufacturers, laboratories, and public health institutions, guided by transparent data sharing and pragmatic implementation pathways. By aligning technological innovation with operational realities and stakeholder needs, the diagnostics community can contribute meaningfully to reducing the burden of pneumococcal disease and strengthening surveillance systems for the future.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumococcal Testing Market, by Type Of Test

  • 8.1. Culture Based
    • 8.1.1. Automated Culture
    • 8.1.2. Conventional Culture
  • 8.2. Molecular
    • 8.2.1. Digital PCR
    • 8.2.2. Multiplex PCR
    • 8.2.3. Real Time PCR
  • 8.3. Serological
    • 8.3.1. Elisa
    • 8.3.2. Rapid Immunoassay

9. Pneumococcal Testing Market, by Technology

  • 9.1. Elisa
    • 9.1.1. Indirect Elisa
    • 9.1.2. Sandwich Elisa
  • 9.2. Immunochromatographic Test
    • 9.2.1. Dot Blot
    • 9.2.2. Lateral Flow Assay
  • 9.3. Next-Generation Sequencing
    • 9.3.1. Illumina Platform
    • 9.3.2. Ion Torrent
  • 9.4. Pcr Assay
    • 9.4.1. Digital PCR
    • 9.4.2. Multiplex PCR
    • 9.4.3. Real Time PCR

10. Pneumococcal Testing Market, by Application

  • 10.1. Carrier Screening
    • 10.1.1. Nasopharyngeal Screening
    • 10.1.2. Oropharyngeal Screening
  • 10.2. Diagnosis
    • 10.2.1. Community Acquired Pneumonia
    • 10.2.2. Meningitis
    • 10.2.3. Otitis Media
  • 10.3. Surveillance
    • 10.3.1. Antibiotic Resistance Monitoring
    • 10.3.2. Serotype Distribution
  • 10.4. Vaccine Evaluation
    • 10.4.1. PostMarketing Surveillance
    • 10.4.2. PreClinical Trials

11. Pneumococcal Testing Market, by End User

  • 11.1. Clinics
    • 11.1.1. Community Health Centers
    • 11.1.2. Outpatient Clinics
  • 11.2. Hospitals
    • 11.2.1. Large Hospitals
    • 11.2.2. Small Hospitals
  • 11.3. Public Health Labs
    • 11.3.1. Local Public Health Labs
    • 11.3.2. State Public Health Labs
  • 11.4. Reference Labs
    • 11.4.1. National Reference Labs
    • 11.4.2. Regional Reference Labs

12. Pneumococcal Testing Market, by Distribution Channel

  • 12.1. Direct Sales
    • 12.1.1. Online Direct
    • 12.1.2. Specialty Sales Team
  • 12.2. Distributors
    • 12.2.1. Local Distributors
    • 12.2.2. National Distributors
  • 12.3. Online
    • 12.3.1. Ecommerce Platforms
    • 12.3.2. Manufacturer Portals

13. Pneumococcal Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pneumococcal Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pneumococcal Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pneumococcal Testing Market

17. China Pneumococcal Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Becton, Dickinson and Company
  • 18.7. Bio-Rad Laboratories, Inc.
  • 18.8. bioMerieux SA
  • 18.9. F. Hoffmann-La Roche Ltd
  • 18.10. Hologic, Inc.
  • 18.11. Meridian Bioscience Inc.
  • 18.12. QIAGEN N.V.
  • 18.13. Seegene Inc.
  • 18.14. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMOCOCCAL TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY AUTOMATED CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CONVENTIONAL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY RAPID IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY INDIRECT ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SANDWICH ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DOT BLOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ILLUMINA PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ION TORRENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NASOPHARYNGEAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OROPHARYNGEAL SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OTITIS MEDIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ANTIBIOTIC RESISTANCE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROTYPE DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY POSTMARKETING SURVEILLANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PRECLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LARGE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SMALL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL PUBLIC HEALTH LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY STATE PUBLIC HEALTH LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NATIONAL REFERENCE LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NATIONAL REFERENCE LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NATIONAL REFERENCE LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGIONAL REFERENCE LABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGIONAL REFERENCE LABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGIONAL REFERENCE LABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE DIRECT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE DIRECT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE DIRECT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SPECIALTY SALES TEAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SPECIALTY SALES TEAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY SPECIALTY SALES TEAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY LOCAL DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ECOMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ECOMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY ECOMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MANUFACTURER PORTALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MANUFACTURER PORTALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY MANUFACTURER PORTALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL PNEUMOCOCCAL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 258. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2018-2032 (USD MILLION)
  • TABLE 264. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, 2018-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 268. LATIN AMERICA PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL TESTING MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY TYPE OF TEST, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY CULTURE BASED, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY MOLECULAR, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY SEROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY ELISA, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY PCR ASSAY, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY CARRIER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY DIAGNOSIS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY SURVEILLANCE, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY VACCINE EVALUATION, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY PUBLIC HEALTH LABS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY REFERENCE LABS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPE PNEUMOCOCCAL TESTING MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)

TABLE 316.